MXPA01008559A - Phenyl- and pyridinyl derivatives - Google Patents

Abstract

The invention relates to compounds of general formula (I), wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;R1 is hydrogen or halogen;or R and R1 may be together -CH=CH-CH=CH-;R2 is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano;R3 is independently from each other hydrogen, lower alkyl or form a cycloalkyl group;R4 is hydrogen, halogen, lower alkyl, lower alkoxy, -N(R5)2, -N(R5)S(O)2-lower alkyl, -N(R5)C(O)R5 or a cyclic tertiary amine of the group (a);R5 is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl;R6 is hydrogen, hydroxy, lower alkyl, -N(R5)CO-lower alkyl, hydroxy-lower alkyl, cyano, -CHO or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R5)-, -(CH2)mO-, -(CH2)mN(R5)-, -N(R5) C(O)-, C(O)O- or -N(R5)(CH2)m-;Y is -(CH2)n-, -O-, -S-, SO2-, -C(O)- or -N(R5)-;Z is=N-, -CH=or -C(C1)=;n is 0 - 4;and, is 1 or 2;and to pharmaceutically acceptable acid addition salts thereof. It has been shown that the compounds of formula (I) have a high affinity to the NK-1 receptor.

Description

DERIVATIVES OF PHENYL AND PYRIDINYL R 2 is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; R; is independently from each other, hydrogen, lower alkyl or forms a cycloalkyl group; hydrogen, halogen, lower alkyl, lower alkoxy, -N (R5) 2, -N (R5) S (O) 2-lower alkyl, -N (R5) C (0) R5 or a cyclic tertiary amine of the Ref group : 132145 RO ' R- is independently from each other, hydrogen, C3_6 cycloalkyl, benzyl or lower alkyl; R 'is hydrogen, hydroxy, lower alkyl, N (R5) CO-lower alkyl, hydroxy-lower alkyl, cyano, -CHO or a 5- or 6-membered heterocyclic group, optionally linked by an alkylene group, X is -C (0) N (R5) -, - (CH2) mO-, - (CH2) mN (R5) -, -N (R5) C (0) -, -C (C) 0-, or -N (R5) (CH2) m-; Y is - (CH2) n, -O-, -S-, -SC-2-, -C (O) - or -N (R5) -; z is = N-, -CH = or -C (C1) =; n is 0-4; and m is 1 or 2; and pharmaceutically acceptable acid derivative salts. The compounds of the formula I and their salts are characterized by valuable therapeutic properties.

Surprisingly it has been found that the compounds of the present invention are antagonists of the neurokinin 1 receptor (NK-1, substance P). Substance P is a naturally occurring undecapeptide belonging to the family of tachykinin peptides, the latter being called for its rapid contractile action in smooth muscle tissue ex-travascular. The substance P receptor is a member of the superfamily of G protein-coupled receptors. The neuropeptide receptor of substance P (NK-1) is widely distributed in the mammalian nervous system (especially brain and spinal ganglia), circulatory system and peripheral tissues (especially the duodenum and jejunum) and is involved in the regulation of a number of diverse biological processes. The central and peripheral actions of mammalian substance P tachykinin have been associated with numerous inflammatory states including migraine, rheumatoid arthritis, asthma and inflammatory bowel disease, as well as the mediation of the emetic reflex and the modulation of central nervous system disorders (CNS). ), such as Parkinson's disease (Neurosci. Res., 1996, 7, 187-214), anxiety (Can. J. Phys., 1997, 75, 612-621) and depression (Science, 1998, 281, 1640). -1645). Evidence for the usefulness of tachykinin receptor antagonists against pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal syndrome, cardiovascular changes, edema, such as edema caused by thermal injury, Chronic inflammatory diseases such as rheumatoid arthritis, asthma / bronchial hyperreactivity and other respiratory diseases, including allergic rhinitis, inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, ocular injury and inflammatory eye diseases, are reported in "Tachykinin Receptor and Tachykinin Receptor Antagonists ", J. Auton. Farmacol. , 13, 23-93, 1993. In addition, Neurokinin 1 receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinin, specifically substance P. Examples of those which substance P has been implicated include disorders of the central nervous system, such as anxiety, depression and psychosis (WO 95/16679, WO 95/18124 and WO 95/23798). Neurokinin-1 receptor antagonists are also useful for the treatment of motion sickness and for the treatment of induced vomiting. Also, in The New England Journal of Medicine, Vol. 340, No. 3 190-195, 1999, the reduction of emesis induced by cisplatin by a selective antagonist of the neurokinin-1 receptor has been described. In addition, US 5,972,938 discloses a method for the treatment of a psychoimmunological or psychosomatic disorder by the administration of a tachykinin receptor antagonist., such as the NK-1 receptor. The objects of the present invention are the compounds of the formula I and the pharmaceutically acceptable derivative salts, the preparation of the aforementioned compounds, the medicaments containing them and their preparation, as well as the use of the compounds mentioned above in the control or prevention of diseases, especially diseases and disorders of the kind referred to at the beginning or in the elaboration of the corresponding medicines. The most preferred indications according to the present invention are those which include disorders of the central nervous system, for example the treatment or prevention of certain depressive disorders or emesis, by the administration of NK-1 receptor antagonists. A major depressive episode has been defined as a period of at least two weeks during which, during most of the day or almost all day, a depressed state or loss of interest or pleasure is experienced in all or almost all of the activities. The following definitions of the general terms used in the present description apply regardless of whether the terms in question appear alone or in combination. In the form in which they have been employed herein, the term "lower alkyl" denotes an alkyl group with a straight or branched chain of 1-7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl and the like. Preferred lower alkyl groups are groups with 1-4 carbon atoms. The term "lower alkoxy" denotes a group in which the alkyl residues are as defined above, which are linked by an oxygen atom. The term "halogen" denotes chlorine, iodine, fluorine and bromine. The term "cycloalkyl" denotes a saturated carbocyclic group, which contains 3-6 carbon atoms. The term "cyclic tertiary amine" denotes, for example, pyrrol-1-yl, imidazol-1-yl, piperidin-1-yl, piperazin-1-yl, morpholin-yl, thiomorpholin-4-yl, 1- oxo-t iomor folin-4-yl or 1,1-dioxo-t iomorpholin-4-yl. The term "5- or 6-membered heterocyclic group" denotes, for example, pyridinyl, pyrimidinyl, oxadiazolyl, triazolyl, tetrazolyl, thiazolyl, thienyl, furyl, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, piperazinyl or piperidyl.

The term "pharmaceutically acceptable acid addition salts" encompasses salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like. Preferred examples are compounds, in which Y is -C (O) - and R 4 is 4-methyl-piperazinyl, for example the following compounds: N- [2-Benzoyl-4- (4-met i 1 -piperaz 1-yl) -phenyl] -2- (3, 5-bis-trifluoromethyl-phenyl) -isobut-iramide, 4-benzoi-1-N- (3,5-bis-trifluoromethyl-benzyl) -N-methyl-6- (4 -met-il-piperazin-1-yl) -nicotinamide and N- (3, 5-Bi-trifluoromet-1-benzyl) -4- (2-chloro-benzoyl) -N-methyl-6- (4-met) i 1-piperazin-1-yl) -nicotinamide. Other compounds which are also preferred are those in which Y is -O- and R 4 is hydrogen, morpholinyl or 4-methyl-piperazinyl. Examples of said compounds are: 2- (3,5-Bis-trifluoromethyl-phenyl) -N-methyl-N- (2-phenoxy-phenyl) -isobutyramide, 2- (3,5-Bis-trifluoromethyl-phenyl) - N-methyl-N- (2-o-tolyloxy-phenyl) -isobut-iramide, 2- (3,5-Bis-tri-fluoromethyl-phenyl) -N- [2- (2,4-dichloro-phenoxy) -phenyl ] -N-met il-isobutyramide, N- (3, 5-Bis-t-fluoromethyl-benzyl) -N-met-il-6-morpholin-4-yl-4-phenoxy-nicotinamide, N- (3, 5-Bis) -trifluoromethyl-1-benzyl) -4- (2-chloro-phenoxy) -N-methyl-6-morpholin-4-yl-nicotinamide, N- (3,5-Bis-trifluoromethyl-1-benzyl) -4- (2 -chloro-phenoxy) -N-met il-6- (4-met i 1 -pipera zin-1-yl) -nicotinamide and N- (3,5-Bis-trifluoromet i 1 -benzyl) -N-met i 1-6-morpholin-4-yl-4-o-tolyloxynicotinamide. Other compounds which are preferred, in which Y is -N (CH3) - and R4 is hydrogen, for example the following compounds: 2- (3,5-Bis-trifluoromethyl-phenyl) -N-met il-N- [ 2- (me; i 1-phenyl-amino) -phenyl] -propionamide, 2- (3,5-Bis-trifluoromethyl-phenyl) -N-met-il-N- [2- (meth-phenyl-amino) -phenyl] -isobutyramide, 2- (3,5-bis-trifluoromethyl-phenyl) -N- [2- (methyl-phenyl-amino) -phenyl] -acetamide and 2- (3,5-Bis-trifluoromethyl-phenyl) - N-methyl-N- [2- (meth-phenyl-amino) -phenyl] -acetamide. The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by the processes described below, which comprise a) reacting a compound of formula with a compound of formula to give a compound of formula wherein R1-R5, R, Y, Z and n have the meanings given above, or b) reacting a compound of formula with a compound of formula to give a compound of formula wherein R1-R5, R, Z, Y and n have the meanings given above or c) reduce a compound of formula to a compound of formula wherein definitions of substituents have been given above, or d) reacting a compound of formula with a compound of formula to give a compound of formula wherein definitions of substituents have been given above, or e) reacting a compound of formula with a formula compue sto to give a compound of formula wherein definitions of substituents have been given above, or f) reducing a compound of formula to give a compound of formula wherein definitions of substituents have been given above, or g) reacting a compound of formula with a compound of formula to give a compound of formula wherein definitions of substituents have been given above, reacting a compound of formula with a compound of formula to give a compound of formula wherein definitions of substituents have been given above, or i) reacting a compound of formula with a compound of formula to give a compound of formula where definitions of substituents have been given previously, or j) modifying one or more substituents R1-R5 or R within the definitions given above, and if desired, converting the compound obtained to a pharmaceutically acceptable acid addition salt. According to variant a) of the process, a compound of formula II, for example 3-amino-4-benzoylpyridine, is cooled in an ice bath and a compound of formula III, for example 2- (2- 3, 5-bis-trifluoromethyl-phenyl) -2-methyl-yl-propionyl in the presence of DIPEA (N-ethyldiisopropylamine) in dichloromethane and then the mixture is stirred at room temperature. The desired compound of the formula 1-1 is isolated after purification in good yields. Variant b) of the process describes the reaction of a compound of formula IV with a compound of formula V, to give a compound of formula 1-2. The reaction is carried out in conventional manner, for example in a solvent, such as a mixture of toluene and triethylamine. The mixture is refluxed for 1 hour. According to variant c) of the process, a compound of formula 1-2 is reduced to a compound of formula 1-4. This reaction is carried out with a reducing agent, such as LiAlH4 or BH3 * THF, in conventional manner. Variant d) of the process describes the reaction of a compound of formula VI with a compound of formula VII, to give a compound of formula 1-2. This reaction is carried out by the deprotonation of a compound of the formula VI with KHMDS (potassium hexamethyldisilazide) and the subsequent addition of a compound of the formula VII. A suitable solvent is tetrahydrofuran. The reaction is carried out at room temperature. According to the variant e) of the process, a compound of the formula 1-5 is prepared. This reaction is carried out by the deprotonation of a compound of the formula VIII with NaH and the subsequent addition of a compound of the formula VII. This reaction is carried out in conventional manner. Another method for the preparation of a compound of formula I is described in variant f) of the process. A compound of formula 1-1 is reduced to a compound of formula 1-3 in conventional manner, for example with LiAlH4 or BH3 »THF. In process variant g) a compound of formula IX is activated with DCC (N, N'-dicyclohexylcarbodiimide) and DMAP (4-N, N-dimethylaminopyridine). The subsequent addition of a compound of the formula X yields a compound of the formula 1-6. According to variant h) a compound of formula IX is activated with CDI (1,1'-carbonyldiimidazole) and the subsequent addition of a compound of formula V gives a compound of formula 1-2. Variant i) of the process describes the process for the preparation of a compound of the formula 1-1, wherein a compound of the formula XII is activated with CDI and the subsequent addition of a compound of the formula II yields a compound of the Formula 1-13. The formation of the salt is carried out at room temperature according to methods which are known per se and which are familiar to any expert in the field. They come into consideration not only salts with inorganic acids, but also salts with organic acids. Hydrochlorides, hydrobromides, sulfates, nitrates, citrates, acetates, maleates, succinates, methanesulfonates, p-toluenesulfonates and the like are examples of such salts. The following schemes 1-7 describe in more detail the processes for the preparation of compounds of the formula I. The starting materials of the formulas IX, X, XI, II, III, XII, XIII, XV, XVII, XVIII, XX , XXII, XXIV and XXV are known compounds or can be prepared according to methods known in the art. The following abbreviations have been used in the schemes: DCC N, N '-dicyclohexylcarbodiimide DMAP 4- (N, N-dimethylamino) pyridine CDI 1, 1'-carbonyldiimidazole KHMDS potassium hexamethyldisilazide DIPEA N-etiIdi isopropyl-amine PivCl pivaloyl chloride It burns 1 The substituents have been given above Scheme 2 The substituents have been given above Scheme 3 The substituents have been given above Scheme 4 The definition of substituents is given above Scheme 5 The definition of substituents has been given above. It's burning 6 I-22 The definition of substituents has been given above.

It burns 7 R, R1, R2, R3 and R5 have the meanings given above. As mentioned at the beginning, the compounds of the formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. It has been found that the compounds of the present invention are antagonists of the neurokinin 1 receptor (NK-1, substance P). The compounds were investigated according to the tests given hereafter. The affinity of the test compounds for the NKi receptor was evaluated with human Ki receptors in CHO cells infected with the human NKi receptor using the Semliki virus expression system) and radiolabelled substance P with [3H] (final concentration 0.6 nM) . Binding assays were performed in buffer or HEPES buffer (50 mM, pH 7.4) containing BSA (0.04%), leupeptin (8 μg / ml), MnCl2 (3mM) and phosphoramidon (2 μM). Binding assays consisted of 250 μl of membrane suspension (1.25xl05 cells / test tube), 0.125 μl of buffer or displacement buffer and 125 μl of substance P [H3]. The displacement curves were determined with at least seven concentrations of the compound. The test tubes were incubated for 60 minutes at room temperature, after which the contents of the tubes were rapidly filtered under vacuum through GF / C filters previously moistened for 60 minutes with PEI (0.3%) with 2 washes of 2 ml. each with buffer or buffer HEPES (50 mM, pH 7.4). The radioactivity retained in the filters was measured by scintillation counting. All assays were performed in triplicate in at least two separate experiments. The affinity for the NK-1 receptor, given as pKi, is between 7.50-9.00 for the preferred compounds. Examples of said compounds are the following: The compounds of the formula I, as well as their pharmaceutically usable acid addition salts, can be used as medicaments, for example in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, for example in the form of tablets, coated tablets, dragees, hard or soft gelatine capsules, solutions, emulsions or suspensions. The administration, however, can be performed rectally, for example, in the form of suppositories, or parenterally, for example in the form of injectable solutions. The compounds of formula I and their pharmaceutically acceptable acid addition salts can be prepared with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees, hard gelatin capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts, etc., can be used as said excipients, for example for tablets, dragees and hard gelatine capsules. Suitable excipients for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols, etc. Suitable excipients for the preparation of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose, etc. Suitable excipients for injectable solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc. Suitable excipients for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols, etc. In addition, the pharmaceutical preparations may contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers., sweeteners, colorants, flavors, salts for the variation of osmotic pressure, buffers or buffers, coating agents or antioxidants. These may also contain other therapeutically valuable substances. The dose can vary within wide limits and could, of course, be adjusted to the individual requirements of each particular case. In general, in the case of oral administration, a daily dose of between 10 and 1000 mg per person of a compound of the general formula I would be appropriate, although the aforementioned upper limit can be overcome when necessary. The following Examples illustrate the present invention without limiting it. All temperatures are given in degrees Celsius.

EXAMPLE 1 N- (4-Benzoyl-pyridin-3-yl) -2- (3, 5-bis-t-rifluoromet-il-phenyl) -N-met-il-isobutyl-amide a) N- (4-Benzoyl-pyridin- 3-yl) -2- (3,5-bis-trifluoromethyl-phenyl) -isobutyl amide A solution of 397 mg (2 mmol) of 3-amino-4-benzoylpyridine and 517 mg (4 mmol) of N-ethyldiisopropylamine in 8 ml of dichloromethane were cooled in an ice bath and a solution of 765 mg (2.4 mmoles) of 2- (3,5-bis-trifluoromethyl-phenyl) -2-methyl-yl-propionyl chloride in them was added dropwise to them. 8 ml of dichloromethane. The reaction mixture was warmed to room temperature and stirred overnight. Water (5 ml) was added and the organic layer was separated. The aqueous phase was extracted with dichloromethane. The combined organic layers were dried (magnesium sulfate) and evaporated. The residue was purified by flash chromatography to give 235 mg (24%) of the title compound as an orange oil. MS m / e (%): 481.3 (M + H +, 100). bj N- (2-Benzoi-1-4-chloro-phenyl) -2- (3,5-bis-t-rifluoromet-il-phenyl) -N-met-il-isobutyl-amide To a solution of 96 mg (0.2 mmol) of N- (4-benzoyl-pyridin-3-yl) -2- (3,5-bis-t -difluoromet-il-phenyl) -isobutyl-amide in 1.2 ml of dimethylformamide, 0.22 ml of a 1M solution of potassium hexamethyldisilazide was added. at 0 ° C. After 30 min, 57 mg of methyl iodide (0.4 mmol) was added and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated, water and dichloromethane were added to the residue, the organic layer was separated and dried over magnesium sulfate. After evaporation of the solvent, the product was purified by flash chromatography to yield 12 mg (12%) of the title compound as a yellow oil. MS m / e (%): 495.2 (M + H +, 100).

EXAMPLE 2 N- (2-Benzoyl-4-chloro-phenyl) -2- (3, 5-bis-trifluoromethyl-phenyl) -N-met il-isobutyl amide to N- (2-benzoyl-4-chloro) phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -isobutyramide To a solution of 233 mg (1 mmol) of 2-amino-5-chlorobenzophenone in 2 ml of 1,2-dichloroethane was added 360 mg (1.2 mmoles) of 2- (3,5-bis-trifluoromethyl-phenyl) -2-methyl-yl-propionic acid and the reaction mixture was stirred at 80 ° C for lh. Dicyclohexyl carbodiimide (194 mg, 1.2 mmol) was added and the stirring was continued overnight at the same temperature. The solvent was evaporated and the obtained residue was purified by silica gel column chromatography to yield 298 mg (58%) of the title compound as a yellow oil. MS m / e (%): 514.2 (M + H +, 100). b) N- (2-Benzoyl-4-chloro-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-met il-isobutyl-amide To a solution of 154 mg (0.3 mmol) of N - (2-benzoyl-4-chloro-phenyl) -2- (3,5-bist rifluoromet-il-phenyl) -isobutyramide in 1 ml of dimethylformamide, 26 mg (0.6 mmol) of sodium hydride (55% suspension) were added. % in mineral oil). After 30 min of stirring at room temperature, 85 mg of methyl iodide (0.6 mmol) was added and the reaction mixture was stirred at 80 ° C overnight. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography to yield 51 mg (32%) of the title compound as white crystals. P.f. 89-91 ° C. MS m / e (%): 528.1 (M + H +, 100).

Example 3 N- (2-Benzoyl-5-chloro-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-methylisobutyramide The title compound was obtained as a yellow oil in comparable yields to those obtained with the procedures described above during the preparation of N- (2-benzoyl-4-chloro-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-methylisobutyramide using 2-amino- 4-chlorobenzophenone instead of 2-amino-5-chlorobenzophenone. MS m / e (%): 528.1 (M + H +, 100).

Example 4 N- (2-Benzoyl-3-chloro-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-isobutyramide The title compound was obtained as a yellowish oil in comparable yields to those obtained with the procedures described above during the preparation of N- (2-benzoyl-4-chloro-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-met il-isobutyl amide, using 2-amino-6-chlorobenzophenone instead of 2-amino-5-chlorobenzophenone. MS m / e (%): 528.1 (M + H +, 100).

Example 5 2- (3, 5-Bis-t, rifluoromet-il-phenyl) -N- [2- (3-chloro-benzoyl) -phenyl] -N-methyl-isobutyramide The title compound was obtained as an yellow color with yields comparable to those obtained with the procedures described above during the preparation of N- (2-benzoyl-4-chloro-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl -isobut iramide, using 2- (3-chlorobenzoyl) -aniline instead of 2-amino-5-chlorobenzofone. MS m / e (%): 528.1 (M + H +, 100).

Example 6 N- (2-Benzoyl-6-methoxy-phenyl) -2- (3, 5-bis-trifluoromethyl-phenyl) -N-methyl-isobutyramide The title compound was obtained as a yellow oil in yields comparable to those obtained with the processes described above during the preparation of N- (2-benzoyl-4-chloro-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-met il-isobut-iramide, using 2-amino-3-methoxybenzophenone instead of 2-amino-5-chlorobenzophenone. MS m / e (%): 523.5 (M + H +, 100).

Example 7 N- (2-Benzoyl-4-methoxy-phenyl) -2- (3,5-bis-t-fluoromet-il-phenyl) -N-met ili-sobut-iramide The title compound was obtained as an yellow color with yields comparable to those obtained with the procedures described above during the preparation of N- (2-benzoyl-4-chloro-phenyl) -2- (3, 5-bis-trifluorornethyl-phenyl) -N-methyl-isobut iramida using 2-amino-5-methoxybenzophenone instead of 2-amino-5-chlorobenzophenone. MS m / e (%): 523.5 (M + H +, 100).

Example 8 (RS) -2- (3,5-Bis -trifluoromethyl-phenyl) -N- [4-chloro-2- (2-chloro-phenylsulfanyl) -phenyl] -N-met-il-propionamide To one solution of 142 mg (0.5 mmol) of 1-chloro-4-methylamino-3- (2-chloro-phenylsulfanyl) -benzene in 2 ml of 1,2-dichloroethane, 172 mg (0.6 mmol) of 2- ( 3,5-bis-trifluoromethyl-phenyl) -propionic acid and the reaction mixture was stirred at 80 ° C for lh. Dicyclohexyl carbodiimide (97 mg, 0.6 mmol) was added and stirring was continued overnight at the same temperature. The solvent was evaporated and the residue obtained was purified by silica gel column chromatography to yield 56 mg (20%) of the title compound as a yellow oil. MS m / e (%): 551.9 (M + H +, 100), 553.9 (M + H +, 90).

Example 9 (RS) -N- (2-Benzoyl-4-chloro-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-propionamide The title compound was obtained as an oil yellow in yields comparable to those obtained with the procedures described above during the preparation of (RS) -2- (3,5-bis-trifluoromethylphenyl) -N- [4-chloro-2- (2-chloro-phenylsulfanyl) phenyl] -N-methypropionamide, using 2-methylamino-5-chlorobenzophenone in place of l-chloro-4-methylamino-3- (2-chloro-phenylsulfanyl) -benzene. MS m / e (%): 514.2 (M + H +, 100).

Example 10 N- [2-Benzoyl-4- (4-methyl-yl-piperazin-1-yl) -phenyl] -2- (3,5-bis-trifluoromethyl-phenyl) -isobutyramide hydrochloride (1: 1) ) 2, 2-Dimethyl-N- [4- (4-methyl-piperazin-1-yl) -phenyl] -propionamide A solution of 5.58 g (29 mmol) of l- (4-aminophenyl) -4- methi piperazine and 3.77 g (29 mmol) of N-ethyldiisopropylamine in 30 ml of tetrahydrofuran were cooled in an ice bath and 3.518 g (29 mmol) of pivaloyl chloride were added dropwise. The suspension was stirred for 18 h at room temperature. Water (30 ml) and dichloromethane (50 ml) were added and the organic layer was separated. The aqueous phase was back extracted with dichloromethane. The combined organic layers were dried (magnesium sulfate) and evaporated to give a white solid. Washing with a mixture of hexane and ethyl acetate (4: 1) yielded 6.69 g (83%) of a white crystalline compound. MS m / e (%): 276.3 (M + H +, 100). b) N- [2-Benzoyl-4- (4-methyl-yl-piperazin-1-yl) -phenyl] -2,2-dimethyl-propionamide A solution of 1375 g (5 mmol) of 2,2-dimethyl- N- [4- (4-methyl-piperazin-1-yl) -phenyl] -propionamide was dissolved in 25 ml of tetrahydrofuran and cooled to -70 ° C. Under an atmosphere of argon, 7.8 ml were slowly added at this temperature (12.5 mmoles) of a 1.6 M solution of n-but-lithium in hexane. The cooling bath was removed and the mixture was stirred for 3 h at room temperature. The reaction mixture was again cooled to -70 ° C and a solution of 1,234 g of N-methoxy-N-methyl-methylbenzamide (7.2 mmol) in 5 ml of tetrahydrofuran was slowly added at -70 ° C. After 10 min, the cooling bath was removed and stirring was continued at room temperature for 1 hour. St. added water (50 ml) to stop the reaction and the mixture was extracted with diethyl ether (three times 50 ml). The organic layer was dried with magnesium sulfate and evaporated to give brown oil, which was purified by flash chromatography with dichloromethane / methanol to yield 315 mg (17%) of the product as a light orange solid. MS m / e (%): 380.4 (M + H +, 100). c) [2-amino-5- (4-methyl-piperazin-1-yl) -phenyl] -fonyl-methylated acid A solution of 0.3 g (0.8 mmol) of N- [2-benzoyl-4- (4 -met-il-piperazin-1-yl) -phenyl] -2,2-dimethyl-il-propionamide in 10 ml of 3N aqueous hydrochloric acid was stirred for 20 h at room temperature. The reaction mixture was extracted once with ethyl acetate, the aqueous layer was made alkaline with a concentrated sodium hydroxide solution and extracted four times with dichloromethane. The combined organic layers were dried over magnesium sulfate and evaporated to yield 245 mg (quantitative) of the product as a yellow oil. MS m / e (%): 296.4 (M + H +, 100). d) N- [2-Benzoyl- (4-methyl-yl-piperazin-1-yl) -phenyl] -2- (3, 5-bis-trifluoromethyl-phenyl) -isobutyramide hydrochloride A solution of 200 mg ( 0.68 mmoles) of [2-amino-5- (4-methyl-piperazin-1-yl) -phenyl] -phenyl-methanone and 219 mg (1.69 mmol) of N-ethyldiisopropylamine in 5 ml of dichloromethane was cooled in a ice bath and a solution of 319 mg (1.0 mmol) of 2- (3,5-bis-trifluoromethyl-phenyl) -2-methyl-yl-propionyl chloride in 2 ml of dichloromethane was added dropwise. The reaction mixture was warmed to room temperature and stirred for 3 hours. Water (5 ml) was added and the layers separated. The aqueous phase was back extracted with dichloromethane. The combined organic layers were dried (magnesium sulfate) and evaporated to give 50 mg of oil. The residue was dissolved in 2 ml of ethyl acetate and 0.018 ml of a 4.75 N solution of hydrochloric acid in ethanol was added. After the addition of 1 ml of diethyl ether, the suspension was stirred for 15 min, the solid was filtered and dried to give 24 mg (6%) of the title compound as a white solid. MS m / e (%): 578.1 (M + H +, 100).

Example 11 4-Benzoyl-N- (3,5-bis-trifluoromethyl-benzyl) -N-methyl-6- (4-methyl-piperazin-1-yl) -nicotinamide hydrochloride (1: 1) a) Hydrochloride 2 Chloro-5- (4, -dimethyl-4,4-dihydro-oxazol-2-yl) -pyridine To 10 g (63.47 mmol) of 2-chloropyridine-5-carboxylic acid were added 60 g (507 mmol) ) of thionyl chloride and the mixture was refluxed for 3 h. Excess thionyl chloride was distilled off, ether (50 ml) added and evaporated to remove thionyl chloride residues. The residue was dissolved in 30 ml of dichloromethane and added dropwise to a solution of 11.88 g (0.133 mmoles) of 2-amino-2-methylpropanol in 30 ml of dichloromethane at 0 ° C. The reaction mixture was stirred for 2 hours at room temperature and 30 ml of water was added. The layers were separated and the aqueous phase was extracted again with dichloromethane. The combined organic layers were dried with magnesium sulfate and evaporated to yield an oily liquid. To the residue was added 22.6 g (190 mmol) of thionyl chloride at 0 ° C and the mixture was stirred for 30 min. Ethyl acetate was added, the mixture was stirred for another 30 min and the crystals were washed with ethyl acetate and ether to yield 14 g (89%) of a white solid. MS m / e (%): 210 (M + H +, 10). b) 1- [5- (4, 4-Dimet-il-4) Hydrochloride, 5-dihydro-oxazol-2-yl) -pyridin-2-yl] -4-methyl-piperazin-2-chloro-5- (4, 4 -dimethyl-4,5-dihydro-oxazol-2-yl) -pyridine was transformed into its free base by dissolving 8.0 g (32 mmol) in a saturated solution of sodium bicarbonate and extracting the base in dichloromethane. The solvent was evaporated and the residue was dissolved in toluene. After the addition of 11.35 g (113 mmol) of N-methylpiperazine, the mixture was refluxed for 36 h. After cooling to room temperature, water (50 ml) and ethyl acetate (150 ml) were added and the aqueous layer was extracted with ethyl acetate (150 ml). The combined organic layers were extracted twice with 1N hydrochloric acid, the acidic aqueous layer was made alkaline with a 28% sodium hydroxide solution and extracted twice with dichloromethane. The organic layer was dried (magnesium sulfate) and evaporated. The residue was crystallized from ethyl acetate / hexane to yield 6.0 g (67%) of a white crystalline compound. MS m / e (%): 274.1 (M + H +, 100). cj [5- (4,4-Dimethyl-4,4-dihydro-oxazol-2-yl) -2- (4-methyl-piperazin-1-yl) -pyridin-4-yl] -pheni-1-methanone 2, 2, 6, 6-Tetramethylpiperidine (0.932 g, 6.6 mmol) was placed in a three-necked flask. Under an argon atmosphere, 10 ml of hexane was added, the solution was cooled to 0 ° C and n-butyllithium (1.6 M solution in hexane) was slowly added. After stirring the yellow suspension for 10 min at 0 ° C, N, N, N ',' tet ramet ilet ilendiamine (767 mg, 6.6 mmol) was added. This mixture was added dropwise to a suspension of 1.65 g (6 mmol) of 1- [5- (4,4-dimethyl-4,5-dihydro-oxazol-2-yl) -pyridin-2-yl] -4-methi 1-piperazine in 20 ml of hexane at -78 ° C. After stirring the yellow solution for 30 mm at this temperature and for 45 mm at 0 ° C, a solution of 1.19 g of N-methoxy-N-methyl-benzamide (7.2 mmole) in 2 ml of hexane was added slowly. 2 ml of tetrahydrofuran at 0 ° C. After 30 min, the cooling bath was removed and stirring was continued at room temperature overnight. Water was added and the mixture was extracted with ethyl acetate. The organic layer was dried (magnesium sulfate) and evaporated to give brown oil, which was purified by flash chromatography with dichloromethane / methanol to yield 1.16 g (51%) of the product as a yellow solid. MS m / e (%): 379.5 (M + H +, 100). d) 4-Benzoyl-6- (4-methyl-piperazin-1-yl) -nicotinic acid 2-amino-2-yl-propyl ester To a solution of 1.13 g (3 mmol) of (5- ( 4, 4 -dimet i 1-4, 5-dihydro-oxazol-2-yl) -2- (4-methyl-piperazin-1-yl) -pyridin-4-yl] -phenyl-methanone in 30 ml of tetrahydrofuran 3 ml of 2 N aqueous hydrochloric acid were added and the reaction mixture was heated at 50 ° C. for 18 h After cooling to room temperature, a 1 N sodium hydroxide solution was added to adjust the pH to 11 and the mixture it was extracted with ethyl acetate, the organic layer was dried (magnesium sulfate) and evaporated to give 1.18 g (quantitative) of the product as a yellow oil MS m / e (%): 481.4 (M + H + , 100). e) 4-Benzoyl-6- (4-methyl-yl-piperazin-1-yl) -nicotinic acid To a solution of 1.15 g (2.9 mmol) of 2-amino-2-methyl-yl-propyl ester of 4-acid Benzoyl-6- (4-methyl-piperazin-1-yl) -nicotinic acid in 20 ml of tetrahydrofuran was added dropwise 367 mg (3.05 mmol) of pivaloyl chloride at 0 ° C. After stirring the yellow suspension at the same temperature for 1 hour, 1M aqueous hydrochloric acid was added. Excess pivaloyl chloride was extracted with dichloromethane, the aqueous layer was made alkaline with a 28% sodium hydroxide solution and extracted twice with dichloromethane. The organic layer was dried (magnesium sulfate) and evaporated. The residue was dissolved in methanol, a solution of 1M aqueous sodium hydroxide was slowly added at 0 ° C and the mixture was heated overnight at 65 ° C. The methanol was evaporated and the aqueous layer was adjusted to pH 5. The solvent was evaporated to yield the product contaminated with sodium chloride, which was used for the next step without any further purification. f) 4-Benzoyl-N- (3,5-bis-trifluoromethylbenzyl) -N-methyl-6- (4-methyl-piperazin-1-yl) -nicotinamide hydrochloride (1: 1) A mixture of 4-acid Benzoyl-6- (4-methyl-piperazin-1-yl) -nicotinic acid (1.5 mmol) of the last step and 3 ml of thionyl chloride was heated at 110 ° C for 1 hour. The excess thionyl chloride was evaporated, the brown oil obtained was redissolved in ether and evaporated again to remove thionyl chloride residues. The residue was dissolved in 2 ml of acetone and 1.16 g (4.5 mmol) of (3,5-bis-trifluoromethylbenzyl) -methyl amine was added. The mixture was stirred for 1.5 h at room temperature. The solvent was evaporated, dichloromethane and water were added, and the aqueous layer was made alkaline with a sodium hydroxide solution (28%). The organic layer was dried (magnesium sulfate), evaporated and purified by flash chromatography to yield 202 mg of oil. This compound was dissolved in 5 ml of diethyl ether and 0.075 ml of a 4.75 N hydrochloric acid solution in ethanol was added. After stirring for 15 min, the suspension was evaporated to dryness, resuspended in 10 ml of diethyl ether, filtered and dried to give 190 mg (21%) of the title compound as a white solid. P.f. 105 ° C, (decomp.). MS m / e (%): 565.2 (M + H +, 100).

Example 12 N- (3,5-Bis-trifluoromethyl-benzyl) -4 - (2-chloro-benzoyl) -N-methyl-6- (4-methyl-piperazin-1-yl) -nicotinamide hydrochloride (1: 1) The title compound was obtained in the form of white crystals, with yields comparable to those obtained with the procedures described above during the preparation of 4-benzoyl-N- (3,5-bis-trifluoromethylbenzyl) hydrochloride - N-methyl-6- (4-methyl-piperazin-1-yl) -nicotinamide (1: 1) using N-methoxy-N-methyl-2-chloro-benzamide in place of N-methoxy-N-methylbenzamide in the step c). P.f. 145 ° C, (decomp.). MS m / e (%): 599.1 (M + H +, 100).

EXAMPLE 13 2-Phenoxy-benzoic acid 3, 5-bis-trifluoromethyl-2-benzyl ester To a solution of 118 mg (0.55 mmol) of 2-phenoxybenzoic acid and 122 mg (0.50 mmol) of 3, 5-bis alcohol (trifluoromethyl) benzyl in 1.5 ml of dichloromethane at 0 ° C, a solution of 124 mg (0.60 mmoles) of 1,3-dicyclohexylcarbodiimide and 7 mg (0.06 mmoles) of 4-dimethylaminopyridine in 1 ml of dichloromethane was added. . The ice bath was removed and the stirring was continued at room temperature overnight. The solvent was removed in vacuo and the residue was redissolved in diethyl ether, filtered and evaporated. The residue was purified by flash chromatography to give 70 mg (32%) of the title compound as white crystals. MS m / e (%): 440 (M +, 51), 347 (39), 227 (36), 197 (100).

Example 14 2-Benzyl-N- (3,5-bis-trifluoromethyl-benzyl) -benzamide To a solution of 255 mg (1.2 mmol) of 2-benzylbenzoic acid in 1.5 ml of tetrahydrofuran at 0 ° C was added 195 mg (1.2 mmol) of 1,1'-carbonyldiimidazole. After stirring for 2.5 h at room temperature, a solution of 243 mg (1.0 mmol) of 3,5-bis (trifluoromethyl) benzylamine in 0.5 ml of tetrahydrofuran was added and the stirring was continued overnight. The solvent was removed in vacuo and the residue was purified by flash chromatography to give 210 mg (49%) of the title compound as white crystals. MS m / e (%): 438 (M + H +, 100).

Example 15 2-Benzyl-N- (3, 5-bis-trifluoromethyl-benzyl) -N-methyl-benzamide To a solution of 100 mg (0.23 mmol) of 2-benzyl-N- (3,5-bis) -trifluoromet-il-benzyl) -benzamide in 1 ml of N, N-dimethylformamide at 0 ° C, 50 mg was added (0.25 mmole) of potassium hexamethyldisilazide. Stirring was continued for 1 h at this temperature and 0.016 ml (0.25 mmoles) of methyl iodide was added. After stirring for 3 h at room temperature, ethyl acetate was added. The mixture was washed with brine, dried (magnesium sulfate) and evaporated. The solvent was removed in vacuo and the residue was purified by flash chromatography to give 90 mg (87%) of the title compound as a colorless oil. MS m / e (%): 452 (M + H +, 100).

EXAMPLE 16 N- (3,5-Bis-trifluoromethyl-benzyl) -N-met i 1-2- (methyl-phenylamino) -benzamide a) N- (3,5-Bis-t rifluoromet-il-benzyl) - 2-phenylamino-benzamide The title compound was obtained in the form of white crystals with yields comparable to those obtained with the procedures described above during the preparation of 2-benzyl-N- (3,5-bis-trifluoromet il- benzyl) -benzamide. MS m / e (%): 477 (M + K +, 24), 461 (M + Na +, 40), 439 (M + H +, 100). b) 2-Benzyl-N- (3, 5-bis-trifluoromethyl-benzyl) -N-met-il-benzamide The title compound was obtained as a colorless oil in yields comparable to those obtained with the procedures described above during the preparation of 2-benzyl-N- (3, 5-bis-trifluoromethyl-benzyl) -N-met i 1 -benzamide. MS m / e (%): 505 (M + K +, 12), 489 (M + Na +, 19), 467 (M + H +, 100).

Example 17 N- (2-Benzenesulfonyl-phenyl) -2- (3,5-bis-trifluoromethylphenyl) -N-methylisobutyramide a) N- (2-Benzenesulfonyl-phenyl) -2- (3,5-bis-trifluoromet) il-phenyl) -isobut iramide A solution of 233 mg (1.0 mmol) of 2-aminophenylphenylsulfone and 0.25 ml (1.5 mmol) of N-ethylisopropylamine in 2 ml of dichloromethane was cooled in an ice bath and a solution of 350 mg (1.1 mmol) of 2- (3-chloride, 5-bis-trifluoromethyl-phenyl) -2-met il-propionyl in 1 ml of dichloromethane was added dropwise. The reaction mixture was stirred at room temperature overnight, evaporated and the residue was purified by flash chromatography to give 490 mg (95%) of the title compound as a pale yellow oil. MS m / e (%): 533 (M + NH 4 +, 60), 516 (M + H +, 100). b) N- (2-Benzenesulfonyl-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-isobutyramide The title compound was obtained as a colorless oil in yields comparable to those obtained with the procedures described above during the preparation of 2-benzyl-N- (3,5-bis-trifluoromethyl-benzyl) -N-methyl-1-benzamide. MS m / e (%): 552 (M + Na +, 40), 530 (M + H +, 100).

Example 18 2- (3,5-Bis-trifluoromethyl-phenyl) -N-methyl-N- (2-phenoxy-phenyl) -isobutyramide The title compound was obtained in the form of a colorless oil with yields comparable to those obtained with the procedures described above during the preparation of N- (2-benzenesulfonyl-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-isobutyramide using 2-phenoxyaniline instead of 2-aminophenyl phenyl sulfone MS m / e (%): 482 (M + H +, 100).

Example 19 N- (2-Benzyl-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-isobutyl-amide The title compound was obtained as a colorless oil with yields comparable to those obtained with the procedures described above during the preparation of N- (2-benzenesulfonyl-phenyl) -2- (3,5-bis-1-fluorometho-1-phenyl) -N-methyl-isobutyramide using 2-benzylaniline instead of 2- aminophenylphenylsulfone. MS m / e (%): 480 (M + H +, 100).

EXAMPLE 20 2- (3,5-Bis-t-rifluoromet-il-phenyl) -N-methyl-N- (2-ot-olyloxy-phenyl) -isobut-iramide The title compound was obtained as pale yellow crystals with yields comparable to those obtained with the processes described above during the preparation of N- (2-benzenesulfonyl-phenyl) -2- (3,5-bis-trif luoromet-il-phenyl) -N-methyl-isobutyramide using 2- (or -loxy) aniline instead of 2-aminophenylphenylsulfone. MS m / e (%): 496 (M + H +, 100).

Example 21 N- (2-Benzoyl-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-isobutyramide The title compound was obtained as a pale yellow oil in yields comparable to those obtained with the procedures described above during the preparation of N- (2-benzenesulfonyl-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-met il-isobutyl-amide using 2-aminobenzophenone in place of 2-aminophenyl-phenyl-sulfone. MS m / e (%): 516 (M + Na +, 55), 49 (M + H +, 100).

Example 22 2- (3,5-Bi-trifluoromethyl-1-phenyl) -N- [2- (2,4-dichloro-phenoxy) -phenyl] -N-met-il-isobutyl-amide The title compound was obtained in the form of a colorless foam with yields comparable to those obtained with the procedures described above during the preparation of N- (2-benzenesulfonyl-phenyl) -2 (3,5-bis-trifluoromethyl-phenyl) -N-methyl-isobutyramide using 2- (2,4-dichlorophenoxy) aniline in place of 2-aminophenylphenylsulfone. MS m / e (%): 549 (M +, 4), 530 (21), 388 (100).

Example 23 2- (3,5-Bis-trifluoromethyl-phenyl) -N- (2-phenylsulfanyl-phenyl) -isobutyl-amide The title compound was obtained as a pale yellow oil with yields comparable to those obtained with the procedures described above during the preparation of N- (2-benzenesulfonyl-phenyl) -2- (3,5-bis-trifluoromethyl-phenyl) -N-met il-isobutyl-amide using 2-aminophenylphenylsulfide in place of 2-aminophenylphenylsulfone. Step b) was not carried out. MS m / e (%): 484 (M + H +, 100).

Example 24 2- (3,5-Bi-trifluoromethyl-phenyl) -N-methyl-N- [2- (methyl-phenylamino) -phenyl] -propionamide a) 2- (3,5-Bis-trifluoromet i 1 phenyl) -N- (2-phenylamino-phenyl) -acetamide To a solution of 545 mg (2.0 mmoles) of 3,5-bis (trifluoromethyl) phenylacetic acid in 2 ml of tetrahydrofuran at 0 ° C was added 325 mg ( 2.0 mmoles) of 1, 1'-carbonyldiimidazole. After stirring for 2.5 h at room temperature, 305 mg (1.66 mmoles) of 2-aminodiphenylamine were added and stirring was continued for 8 h at 60 ° C. The solvent was removed in vacuo and the residue was purified by flash chromatography to give 480 mg (66%) of the title compound as white crystals. MS m / e (%): 439 (M + H +, 35), 142 (100). b) 2- (3,5-Bis-trifluoromethyl-phenyl) -N-methyl-N- [2- (methylphenyl-amino) -phenyl] -propionamide To a solution of 389 mg (0.89 mmol) of 2- ( 3, 5-bis-trifluoromethyl-phenyl) -N- (2-phenylamino-phenyl) -acetamide in 1 ml of N, N-dimethylformamide at 0 ° C was added 560 mg (2.66 mmoles) of potassium hexamethyldisilazide. Stirring was continued for 1 h at this temperature and 510 mg (2.66 mmoles) of methyl iodide was added. After stirring for 3 h at room temperature, ethyl acetate was added. The mixture was washed with brine, dried (magnesium sulfate) and evaporated. The solvent was removed in vacuo and the residue was purified by flash chromatography to give 110 mg (25%) of the title compound as white crystals. MS m / e (%): 480 (M +, 76), 239 (100).

Example 25 2- (3,5-Bis-trifluoromethyl-phenyl) -N-methyl-N- [2- (methylphenyl-amino) -phenyl] -isobutyl-amide To a solution of 52 mg (0.11 mol) of 2- ( 3, 5-bis-trifluoromethyl-phenyl) -N-methyl-N- [2- (methy-phenyl-amino) -phenyl] -propionamide in 0.5 ml of N, N-dimethylformamide at 0 ° C, they added 32 mg (0.16 mmol) of potassium hexamethyldisilazide. Stirring was continued for 1 h at this temperature and 30 mg (0.16 mmol) of methyl iodide was added. After stirring for 3 h at room temperature, ethyl acetate was added. The mixture was washed with brine, dried (magnesium sulfate) and evaporated. The solvent was removed in vacuo and the residue was purified by flash chromatography to give 54 mg (quantitative) of the title compound as a colorless oil. MS m / e (%): 494 (M +, 87), 195 (100).

Example 26 2- (3,5-Bis-trifluoromethyl-phenyl) -N- [2- (methyl-phenyl-amino) -phenyl] -acetamide The title compound was obtained in the form of white crystals with comparable yields of those obtained with the procedures described above during the preparation of 2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-N- [2- (methyl-phenylamino) -phenyl] -propionamide using N-methyl- N-Phenylbenzene-1,2-diamine instead of 2-aminodiphenylamine. Step b) was not carried out. MS m / e (%): 453 (M + H +, 100).

Example 27 2- (3,5-Bis-trifluoromethyl-phenyl) -N-methyl-N- [2- (methyl-phenylamino) -phenyl] -acetamide The title compound was obtained in the form of a colorless oil with comparable yields of those obtained with the procedures described above during the preparation of 2- (3,5-bis-trifluoromethyl-phenyl) -N-methyl-N- [2- (methy1-phenylamino) -phenyl] -propionamide using N, N ' -dimethyl-N-phenyl-benzene-1,2-diamine in place of 2-aminodiphenylamine. Step b) was not carried out. MS m / e (%); 467 (M + H +, 100).

Example 28 N- (3,5-Bis-trifluoromethyl-benzyl) -N-methyl-6-morpholin-4-yl-4-phenoxy-nicotinamide a) 6-Chloro-4-phenoxy-nicotinic acid ethyl ester To a solution of 196 mg (approximately 4 mmol) of a dispersion of sodium hydride in mineral oil (approximately 50%) in 15 ml of N, N-dimethylformamide, a solution of 385 mg was added dropwise ( 4.09 mmoles) of phenol in 10 ml of N, N-dimethylformamide at room temperature under an argon atmosphere. After 15 min, this solution was slowly added by cannula to a solution of 4,6-dichloro-nicotinic acid ethyl ester in 20 ml of N, -dimethyl ilformamide at room temperature. After 2 h, the reaction was quenched with 20 ml of water. The mixture was extracted with 3 50 ml portions of ethyl acetate. The combined organic extracts were dried with sodium sulfate and concentrated. After drying under vacuum at 50 ° C and flash column chromatography, 800 mg (70.4%) of the title compound was obtained as a white solid. As a side product, 130 mg (11.4%) of 4-chloro-6-phenoxy nicotinic acid ethyl ester was also isolated. MS m / e (%): 277 (M + 81), 232 ([M-OEt] +, 100). b) 6-Morpholin-4-yl-4-phenoxy-nicotinic acid ethyl ester A solution of 130 mg (0.468 mmol) of 6-chloro-4-phenoxy nicotinic acid ethyl ester0.040 ml (0.47 mmoles) of morpholine and 0.065 ml (0.47 mmoles) of triethylamine in 7 ml of tetrahydrofuran was stirred under reflux for 40 h. After cooling to room temperature, the reaction mixture was filtered, diluted with ethyl acetate and washed with water and a saturated aqueous solution of sodium chloride. The organic layer was dried with sodium sulfate and concentrated. Flash column chromatography afforded 66 mg (43%) of the title compound as a white solid. MS m / e (%): 329 (M + H +, 100). c) 6-Morpholin-4-yl-4-phenoxy-nicotinic acid A mixture of 66 mg (0.20 mmol) of 6-morpholin-4-yl-4-phenoxy nicotinic acid ethyl ester, 2 ml of methanol and 2 ml of a solution of aqueous sodium hydroxide IN was stirred at room temperature for 1 h. The reaction mixture was diluted with water and washed with tert-butyl methyl ether. The aqueous layer was acidified to pH 4-5 with a concentrated hydrochloric acid solution and extracted with 3 portions of dichloromethane. The combined organic layers were washed with a saturated aqueous sodium chloride solution and dried with sodium sulfate. Concentration gave 46 mg (77%) of the title compound as a white solid. MS m / e (%): 301 (M + H +, 100). d) N- (3, 5-Bis-trifluoromet-il-benzyl) -N-methyl-6-morpholin-4-yl-4-phenoxy-nicotinamide A mixture of 46 mg (0.15 mmoles) of 6-morpholin-4 acid -yl-4-phenoxy-nicotinic acid, 43 mg (0.17 mmol) of (3,5-bis-trifluoromethyl-benzyl) -methylamine, 32 mg (0.17 mmol) of l- (3-diaminopropyl) -3-ethyl hydrochloride Carbodiimide and a catalytic amount of 4 - (N, N-dimethylamino) -pyridine in 3 ml of dichloromethane was stirred at room temperature overnight. The reaction mixture was diluted with water, adjusted to pH 6 with a saturated aqueous solution of ammonium chloride and extracted with dichloromethane. The combined organic layers were washed with a saturated aqueous sodium chloride solution, dried with sodium sulfate and concentrated. Flash column chromatography afforded 68 mg (83%) of the title compound as a white solid. MS m / e (%): 540 (M + H +, 100).

Example 29 N- (3,5-Bis-trifluoromethyl-benzyl) -4- (2-chloro-phenoxy) -N-methyl-6-morpholin-4-yl-nicotinamide The title compound was obtained as a solid white with yields comparable to those obtained with the procedures described above during the preparation of N- (3,5-bis-trifluoromethyl-benzyl) -N-methyl-6-morpholin-4-yl-4-phenoxy-nicot inamide (Example 28) using 2-chlorophenol in place of phenol in step a). MS m / e (%): 574 (M + H +, 100).

EXAMPLE 30 N- (3,5-Bis-t-rifluoromethyl-benzyl) -4- (2-chloro-phenoxy) -N-meth i 1-6- (-methylpiperazin-1-yl) -nicotinamide The title compound it was obtained as a white solid in yields comparable to those obtained with the procedures described above during the preparation of N- (3,5-bis-trifluoromethyl-benzyl) -N-met-il-6-morpholine- 4 - il-phenoxy nicotinamide (Example 28) using 2-chlorophenol in place of phenol in step a) and 1-methylpiperazine in place of morpholine in step b). MS m / e (%): 587 (M + H +, 100).

Example 31 N- (3,5-Bis-trifluoromethyl-benzyl) -N-methyl-6-morpholin-4-yl-4-o-tolyloxy-nicotinamide The title compound was obtained as a white solid in yields comparable to those obtained with the procedures described above during the preparation of N- (3,5-bis-trifluoromethyl-benzyl) -N-methyl-6-morpholin-4-yl-4-phenoxy-nicot inamide (Example 28) using o-cresol in place of phenol in step a). MS m / e (%): 554 (M + H +, 100).

Example A Tablets with the following composition can be produced in conventional manner: mg / tablet Active substance 5 Lactose 45 Corn starch 15 Microcrystalline cellulose 34 Magnesium stearate 1 Tablet weight: 100 Example B Capsules are manufactured with the following composition: mg / capsule Active substance 10 Lactose 155 Corn starch 30 Talc 5 Weight of capsule filling: 200 The active substance, lactose and corn starch are first mixed using a mixer and then a grinding apparatus. The mixture is returned to the mixer, talc is added and everything is mixed. Hard gelatine capsules are filled with this mixture by means of an apparatus.

Example C Suppositories are manufactured with the following composition mg / suppository Active substance 15 Suppository mass 1285 Total 300 The suppository mass is melted in a glass or steel vessel, mixed and cooled to 45 ° C. Then, the finely powdered active substance is added and stirred until it has completely dispersed. The mixture is deposited in suppository molds of the appropriate size, allowed to cool, the suppositories are removed from the molds and individually packaged in wax paper or aluminum foil.

It is noted that in relation to this date, the best method known to the applicant, to carry out the aforementioned invention, is that which is clear from the present description of the invention.

Claims (14)

CLAIMS Having described the invention as above, it is claimed as. property contained in the following claims:

1. Compounds of the general formula characterized in that R is hydrogen, alkyl- (C? ~ C7), alkoxy- (C? ~ C), halogen or trifluoromethyl; R1 is hydrogen or halogen, with the proviso that R1 at position 4 is not bromine or iodine; or R and R1 can be together -CH = CH-CH = CH-; R2 is hydrogen, halogen, trifluoromethyl, alkoxy- (C? -C7) or cyano, with the proviso that R2 is not hydrogen, if X is -C (0) 0-; R3 is independently of one another, hydrogen, alkyl- (C? -C7) or forms a cycloalkyl group; R is hydrogen, halogen, alkyl- (C? -C7), alkoxy- (C? -C7), -N (R5) 2, -N (R5) S (O) 2 -alkyl- (C? -C7) , -N (R5) C (0) R5 or a cyclic tertiary amine selected from the group consisting of pyrrol-1-yl, imidazol-1-yl, piperidin-1-yl, piperazin-1-yl, morpholin-4- ilo, thiomorpholin-4-yl, 1-oxo-t -omorpholin-4-yl or 1,1-dioxo-t -omorpholin-4-yl, which may be substituted or unsubstituted by hydroxy, alkyl- (C? -C7) ), N (R5) CO- (C1-C7) alkyl, hydroxy- (C? -C7) alkyl, cyano, -CHO, or a 5- or 6-membered heterocyclic group, optionally linked via a selected alkylene group of the group consisting of pyridinyl, pyrimidinyl, oxadiazolyl, triazolyl, tetrazolyl, thiazolyl, thienyl, furyl, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, piperazinyl or piperidinyl; R "is independently from each other, hydrogen, C3-6 cycloalkyl, benzyl or alkyl- (Cj.-C7); X is -C (0) N (R5) -, - (CH2) mO-, - (CH2) mN (R5) -, -N (R5) C (0) -, -C (C) 0-, or -N (R5) (CH2) m-; is - (CH2) -O-, -S-, -S02-, -C (O) - or -N (R5) - R- is C3-C6 cycloalkyl, benzyl or lower alkyl; es = N-, -CH = or -C (C1) =; n is 0-4; and m is 1 or 2; and salts derived from a pharmaceutically acceptable acid addition.

2. A compound according to claim 1, characterized in that wherein Y is -C (O) - and R4 is 4-methylpiperazinyl.

3. A compound according to claim 2, characterized in that it is N- [2-Benzoyl-4- (4-methyl-piperazin-1-yl) -phenyl] -2- (3,5-bis-trifluoromet-il-phenyl) ) -isobut iramide, 4-Benzoyl-N- (3,5-bis-trifluoromethyl-benzyl) -N-methyl-6- (4-methyl-piperazin-1-yl) -nicotinamide and N- (3, 5-Bis-t-rifluoromethyl-benzyl) -4- (2-chloro-benzoyl) -N-methyl-6- (4-methyl-piperazin-1-yl) -nicotinamide.

4. A compound according to claim 1, characterized in that Y is -O-, and R4 is hydrogen, 4-methyl-piperazinyl or morpholinyl.

5. A compound according to claim 4, characterized in that it is 2- (3,5-Bis-trifluoromethyl-phenyl) -N-met il-N- (2-phenoxy-phenyl) -isobut-iramide, 2- (3 , 5-Bis-trifluoromethyl-phenyl) -N-methyl-N- (2-o-tolyloxy-phenyl) -isobut-iramide, 2- (3,5-Bis-trifluoromethyl-phenyl) -N- [2- ( 2,4-dichloro-phenoxy) -phenyl] -N-methyl-isobutyramide, N- (3,5-Bis-t rifluoromethyl-benzyl) -N-meth i 1-6-morpholin-4-yl-4-phenoxynicotinamide , N- (3, 5-Bis-trifluoromet-il-benzyl) -4- (2-chloro-phenoxy) -N-methyl-6-morpholin-4-yl-nicotinamide, N- (3,5-Bis-trifluoromet) il-benzyl) -4- (2-chloro-phenoxy) -N-methyl-6- (4-methyl-piperazin-1-yl) -nicotinamide and N- (3,5-Bis-t-rifluoromethyl-benzyl) - N-methyl-6-morpholin-4-yl-4-o-tolyloxynicot inamide.

6. A compound according to claim 1, characterized in that Y is -N (CH3) - and R4 is hydrogen.

A compound according to claim 6, characterized in that it is 2- (3,5-Bis-trifluoromethyl-phenyl) -N-met il-N- [2- (methyl-phenyl-amino) -phenyl] -propionamide 2- (3, 5-Bis-t-rifluoromethyl-phenyl) -N-met-il-N- [2- (methyl-phenyl-amino) -phenyl] -isobut-iramide, 2- (3,5-Bis-trifluoromet) il-phenyl) -N- [2- (methyl-phenyl-amino) -phenyl] -acetamide and 2- (3,5-Bis-t -difluoromet-il-phenyl) -N-methyl-N- [2- (methyl phenyl-amino) -phenyl] -acetamide.

8. A medicament characterized in that it contains one or more compounds as claimed in any of claims 1-7 and the pharmaceutically acceptable excipients.

9. A medicament according to claim 8, characterized in that it is for the treatment of diseases related to NK-1 receptor antagonists.

10. A process for preparing a compound of formula I as defined in claim 1, characterized in that it comprises a) reacting a compound of formula with a compound of formula to give a compound of formula wherein R1-R5, R, Y, Z and n have the meanings given in claim 1, or b) reacting a compound of formula with a compound of formula to give a compound of formula wherein R, 1 1 -R °, R, Z, Y and n have the meanings given in claim 1, or c) reducing a compound of formula to a compound of formula wherein the definitions of substituents have been given in claim 1, or d) reacting a compound of formula with a compound of formula to give a compound of formula wherein the definitions of substituents have been given in claim 1, or e) reacting a compound of formula with a compound of formula to give a compound of formula wherein definitions of substituents have been given in claim 1, or f) reducing a compound of formula to give a compound of formula wherein the definitions of substituents have been given in claim 1, or g) reacting a compound of formula with a compound of formula to give a compound of formula wherein the definitions of substituents have been given in claim 1, or h) reacting a compound of formula with a compound of formula to give a compound of formula wherein the definitions of substituents have been given in claim 1, or i) reacting a compound of formula with a compound of formula to give a compound of formula wherein the definitions of substituents have been given in claim 1, or j) modifying one or more substituents R1-R5 or R within the definitions given above, if desired, convert the obtained compound to a pharmaceutically acceptable acid addition salt.

11. A compound according to any of claims 1-7, characterized in that it is prepared by a process as claimed in claim 8 or by an equivalent method.

12. The use of a compound in any of claims 1-7 for the treatment of diseases.

13. The use of a compound in any of the rei indications 1-7 for the treatment of diseases related to the NK-1 receptor.

14. The use of a compound of the formula I in any of claims 1-7 for the manufacture of a medicament containing a compound of the formula I for the treatment of diseases related to the NK-1 receptor. SUMMARY OF THE INVENTION The present invention relates to compounds of the general formula (I), wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R1 is hydrogen or halogen; or R and R1 can be together -CH = CH-CH = CH-; R < is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; R 'is independently from each other, hydrogen, lower alkyl or forms a cycloalkyl group; R 'is hydrogen, halogen, lower alkyl, lower alkoxy, -N (R5) 2, -N (R5) S (O) 2-lower alkyl, -N (R5) C (0) R5 or a cyclic tertiary amine of the group R- is independently from each other, hydrogen, C3-6 cycloalkyl, benzyl or lower alkyl; R < is hydrogen, hydroxy, lower alkyl, N (R5) CO-lower alkyl, hydroxy-lower alkyl, cyano, -CHO or a 5- or 6-membered heterocyclic group, optionally linked by an alkylene group, X is -C (0 ) N (R5) -, - (CH2) mO-, - (CH2) mN (R5) -, -N (R5) C (0) -, -C (C) 0-, or -N (R5) ( CH2) m-; Y is - (CH2) n, -O-, -S-, -S02_, -C (O) - or -N (R5) -; z is = N-, -CH = or -C (C1) =; is 0-4; and m is 1 or 2; and salts derived from a pharmaceutically acceptable acid addition. It has been shown that the compounds of formula I have a higher affinity for the NK-1 receptor.